Viser 1 - 50 av 103 resultater
Tid Selskap Tittel Sektor Kategori
18 Nov 2025
22:01 CET
ARGENX SE argenx Announces Results of Extraordinary General Meeting of Shareholders 20103010 Biotechnology Other subject
30 Oct 2025
07:00 CET
ARGENX SE argenx Reports Third Quarter 2025 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
29 Oct 2025
16:00 CET
ARGENX SE argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients 20103010 Biotechnology Other subject
23 Oct 2025
07:00 CEST
ARGENX SE argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 20103010 Biotechnology Other subject
15 Oct 2025
07:00 CEST
ARGENX SE argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session 20103010 Biotechnology Other subject
03 Oct 2025
22:01 CEST
ARGENX SE argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 20103010 Biotechnology Other subject
28 Aug 2025
07:00 CEST
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
25 Aug 2025
07:00 CEST
ARGENX SE argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG 20103010 Biotechnology Other subject
19 Aug 2025
07:00 CEST
ARGENX SE argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 20103010 Biotechnology Other subject
12 Aug 2025
12:45 CEST
ARGENX SE argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis 20103010 Biotechnology Other subject
31 Jul 2025
07:00 CEST
ARGENX SE argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
24 Jul 2025
07:00 CEST
ARGENX SE argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 20103010 Biotechnology Other subject
30 Jun 2025
07:00 CEST
ARGENX SE argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes 20103010 Biotechnology Other subject
20 Jun 2025
19:00 CEST
ARGENX SE argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
11 Jun 2025
00:01 CEST
ARGENX SE argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease 20103010 Biotechnology Other subject
03 Jun 2025
07:00 CEST
ARGENX SE argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference 20103010 Biotechnology Other subject
28 May 2025
22:01 CEST
ARGENX SE argenx Announces Results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
08 May 2025
07:00 CEST
ARGENX SE argenx Reports First Quarter 2025 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
06 May 2025
07:00 CEST
ARGENX SE argenx to Present at BofA Securities 2025 Health Care Conference 20103010 Biotechnology Other subject
01 May 2025
07:00 CEST
ARGENX SE argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 20103010 Biotechnology Other subject
28 Apr 2025
07:00 CEST
ARGENX SE argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 20103010 Biotechnology Other subject
11 Apr 2025
22:01 CEST
ARGENX SE argenx Announces Annual General Meeting of Shareholders on May 27, 2025 20103010 Biotechnology Other subject
10 Apr 2025
23:47 CEST
ARGENX SE argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
08 Apr 2025
07:00 CEST
ARGENX SE argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP 20103010 Biotechnology Other subject
07 Mar 2025
07:00 CET
ARGENX SE argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting 20103010 Biotechnology Other subject
27 Feb 2025
07:00 CET
ARGENX SE argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update 20103010 Biotechnology Other subject
25 Feb 2025
07:00 CET
ARGENX SE argenx to Present at TD Cowen 45th Annual Healthcare Conference 20103010 Biotechnology Other subject
20 Feb 2025
07:00 CET
ARGENX SE argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 20103010 Biotechnology Other subject
13 Jan 2025
07:00 CET
ARGENX SE argenx Highlights 2025 Strategic Priorities 20103010 Biotechnology Other subject
06 Jan 2025
07:00 CET
ARGENX SE argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
27 Dec 2024
07:00 CET
ARGENX SE argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
26 Nov 2024
07:00 CET
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
20 Nov 2024
07:00 CET
ARGENX SE argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies 20103010 Biotechnology Other subject
11 Nov 2024
13:30 CET
ARGENX SE argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China 20103010 Biotechnology Other subject
05 Nov 2024
07:00 CET
ARGENX SE argenx to Participate at Upcoming Investor Conferences 20103010 Biotechnology Other subject
31 Oct 2024
07:00 CET
ARGENX SE argenx Reports Third Quarter 2024 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
24 Oct 2024
07:00 CEST
ARGENX SE argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 20103010 Biotechnology Other subject
15 Oct 2024
07:00 CEST
ARGENX SE argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions 20103010 Biotechnology Other subject
19 Sep 2024
07:00 CEST
ARGENX SE argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
28 Aug 2024
07:00 CEST
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
25 Jul 2024
07:00 CEST
ARGENX SE argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
18 Jul 2024
07:00 CEST
ARGENX SE argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024 20103010 Biotechnology Other subject
16 Jul 2024
06:30 CEST
ARGENX SE argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China 20103010 Biotechnology Other subject
25 Jun 2024
22:30 CEST
ARGENX SE argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting 20103010 Biotechnology Other subject
21 Jun 2024
22:50 CEST
ARGENX SE argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
17 Jun 2024
07:00 CEST
ARGENX SE argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 20103010 Biotechnology Other subject
04 Jun 2024
07:00 CEST
ARGENX SE argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference 20103010 Biotechnology Other subject
09 May 2024
07:00 CEST
ARGENX SE argenx Reports First Quarter 2024 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
07 May 2024
23:30 CEST
ARGENX SE argenx announces results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
07 May 2024
07:00 CEST
ARGENX SE argenx to Present at BofA Securities 2024 Health Care Conference 20103010 Biotechnology Other subject